• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于理解 SARS-CoV-2 变体抗体逃逸的抗原空间框架。

An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants.

机构信息

Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

出版信息

Viruses. 2021 Oct 6;13(10):2009. doi: 10.3390/v13102009.

DOI:10.3390/v13102009
PMID:34696440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8537311/
Abstract

The evolution of mutations in SARS-CoV-2 at antigenic sites that impact neutralizing antibody responses in humans poses a risk to immunity developed through vaccination and natural infection. The highly successful RNA-based vaccines have enabled rapid vaccine updates that incorporate mutations from current variants of concern (VOCs). It is therefore important to anticipate future antigenic mutations as the virus navigates the heterogeneous global landscape of host immunity. Toward this goal, we survey epitope-paratope interfaces of anti-SARS-CoV-2 antibodies to map an antigenic space that captures the role of each spike protein residue within the polyclonal antibody response directed against the ACE2-receptor binding domain (RBD) or the N-terminal domain (NTD). In particular, the antigenic space map builds on recently published epitope definitions by annotating epitope overlap and orthogonality at the residue level. We employ the antigenic space map as a framework to understand how mutations on nine major variants contribute to each variant's evasion of neutralizing antibodies. Further, we identify constellations of mutations that span the orthogonal epitope regions of the RBD and NTD on the variants with the greatest antibody escape. Finally, we apply the antigenic space map to predict which regions of antigenic space-should they mutate-may be most likely to complementarily augment antibody evasion for the most evasive and transmissible VOCs.

摘要

SARS-CoV-2 抗原位点突变的进化会影响人类中和抗体反应,从而对通过疫苗接种和自然感染产生的免疫构成威胁。高度成功的基于 RNA 的疫苗能够快速更新疫苗,纳入当前关注变体 (VOC) 的突变。因此,重要的是要预测未来的抗原突变,因为病毒在宿主免疫的异质全球景观中导航。为此,我们调查了抗 SARS-CoV-2 抗体的表位-互补位界面,以绘制一个抗原空间,该空间捕获了针对 ACE2 受体结合域 (RBD) 或 N 端结构域 (NTD) 的多克隆抗体反应中每个刺突蛋白残基的作用。特别是,抗原空间图基于最近发表的表位定义,通过在残基水平注释表位重叠和正交性来构建。我们将抗原空间图用作框架,以了解九个主要变体上的突变如何导致每种变体逃避中和抗体。此外,我们确定了跨越 RBD 和 NTD 的正交表位区域的突变组合,这些变体的抗体逃逸能力最强。最后,我们应用抗原空间图来预测如果发生突变,抗原空间的哪些区域最有可能互补地增强最具逃逸性和传染性的 VOC 的抗体逃逸。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/8b01ccd0cffc/viruses-13-02009-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/2c3c59596a7a/viruses-13-02009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/f73a981d3438/viruses-13-02009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/5b3d9514e3fd/viruses-13-02009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/8b01ccd0cffc/viruses-13-02009-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/2c3c59596a7a/viruses-13-02009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/f73a981d3438/viruses-13-02009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/5b3d9514e3fd/viruses-13-02009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9d/8537311/8b01ccd0cffc/viruses-13-02009-g004.jpg

相似文献

1
An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants.用于理解 SARS-CoV-2 变体抗体逃逸的抗原空间框架。
Viruses. 2021 Oct 6;13(10):2009. doi: 10.3390/v13102009.
2
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.全面绘制 SARS-CoV-2 RBD 特异性中和抗体的结合热点,用于跟踪免疫逃逸变异株。
Genome Med. 2021 Oct 14;13(1):164. doi: 10.1186/s13073-021-00985-w.
3
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.识别 SARS-CoV-2 刺突蛋白主要和次要表位的单克隆抗体的中和效力受 B.1.1.7 变异株的影响。
Immunity. 2021 Jun 8;54(6):1276-1289.e6. doi: 10.1016/j.immuni.2021.03.023. Epub 2021 Apr 1.
4
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.针对关注的 SARS-CoV-2 变体的中和抗体的表位分类和 RBD 结合特性。
Front Immunol. 2021 Jun 4;12:691715. doi: 10.3389/fimmu.2021.691715. eCollection 2021.
5
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.SARS-CoV-2 奥密克戎、贝塔和德尔塔 plus 变体共享的 N417 依赖性表位。
J Virol. 2022 Aug 10;96(15):e0055822. doi: 10.1128/jvi.00558-22. Epub 2022 Jul 13.
6
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
7
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.奥密克戎逃避了大多数现有的 SARS-CoV-2 中和抗体。
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.
8
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.一项结构-功能分析表明,SARS-CoV-2 BA.2.86 平衡了抗体逃逸和 ACE2 亲和力。
Cell Rep Med. 2024 May 21;5(5):101553. doi: 10.1016/j.xcrm.2024.101553. Epub 2024 May 8.
9
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.广谱中和抗体可克服 SARS-CoV-2 奥密克戎抗原漂移。
Nature. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2. Epub 2021 Dec 23.
10
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain.关于 SARS-CoV-2 奥密克戎变异株受体结合域突变特征的研究进展。
Cell Rep Med. 2022 Jan 24;3(2):100527. doi: 10.1016/j.xcrm.2022.100527. eCollection 2022 Feb 15.

引用本文的文献

1
The changing health impact of vaccines in the COVID-19 pandemic: A modeling study.在 COVID-19 大流行中,疫苗对健康影响的变化:一项建模研究。
Cell Rep. 2023 Apr 25;42(4):112308. doi: 10.1016/j.celrep.2023.112308. Epub 2023 Mar 15.
2
Learned features of antibody-antigen binding affinity.抗体-抗原结合亲和力的习得特征。
Front Mol Biosci. 2023 Feb 21;10:1112738. doi: 10.3389/fmolb.2023.1112738. eCollection 2023.
3
Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies.病毒表位表面的复杂性作为疫苗和治疗性抗体的逃避目标。

本文引用的文献

1
Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.关注的 SARS-CoV-2 变体的人类 ACE2 和 Spike RBD 之间的差异相互作用。
J Chem Theory Comput. 2021 Dec 14;17(12):7972-7979. doi: 10.1021/acs.jctc.1c00965. Epub 2021 Dec 3.
2
Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.康复期和疫苗血清对严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)Mu变异株的中和作用
N Engl J Med. 2021 Dec 16;385(25):2397-2399. doi: 10.1056/NEJMc2114706. Epub 2021 Nov 3.
3
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
Front Immunol. 2022 Jun 17;13:904609. doi: 10.3389/fimmu.2022.904609. eCollection 2022.
4
Special Issue "Emerging Viruses 2021: Surveillance, Prevention, Evolution and Control".特刊征稿:2021 年新兴病毒:监测、预防、演变与控制
Viruses. 2022 Apr 15;14(4):815. doi: 10.3390/v14040815.
5
A structural dynamic explanation for observed escape of SARS-CoV-2 BA.2 variant mutation S371L/F.对观察到的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)BA.2变体突变S371L/F逃逸现象的结构动力学解释
bioRxiv. 2022 Mar 2:2022.02.25.481957. doi: 10.1101/2022.02.25.481957.
6
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain.关于 SARS-CoV-2 奥密克戎变异株受体结合域突变特征的研究进展。
Cell Rep Med. 2022 Jan 24;3(2):100527. doi: 10.1016/j.xcrm.2022.100527. eCollection 2022 Feb 15.
7
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株突变图谱的见解。
bioRxiv. 2021 Dec 10:2021.12.06.471499. doi: 10.1101/2021.12.06.471499.
循环的 SARS-CoV-2 变体对 mRNA 疫苗诱导免疫的影响。
Nature. 2021 Dec;600(7889):523-529. doi: 10.1038/s41586-021-04085-y. Epub 2021 Oct 11.
4
Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses.SARS-CoV-2 病毒的德尔塔和德尔塔+变体的进化分析。
J Autoimmun. 2021 Nov;124:102715. doi: 10.1016/j.jaut.2021.102715. Epub 2021 Aug 11.
5
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.印度马哈拉施特拉邦第二波新冠疫情中出现的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白突变,L452R、T478K、E484Q和P681R
Microorganisms. 2021 Jul 20;9(7):1542. doi: 10.3390/microorganisms9071542.
6
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.2021 年 7 月,马萨诸塞州巴恩斯特布尔县与大型公众集会相关的 SARS-CoV-2 感染暴发,包括 COVID-19 疫苗突破性感染。
MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-1062. doi: 10.15585/mmwr.mm7031e2.
7
The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic.在不断演变的 COVID-19 大流行中,关注的 SARS-CoV-2 变体的起源和潜在未来。
Curr Biol. 2021 Jul 26;31(14):R918-R929. doi: 10.1016/j.cub.2021.06.049. Epub 2021 Jun 23.
8
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.MW06 是一种人源单克隆抗体,对 SARS-CoV-2 和 SARS-CoV 均具有交叉中和活性。
MAbs. 2021 Jan-Dec;13(1):1953683. doi: 10.1080/19420862.2021.1953683.
9
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.一种从 COVID-19 患者中筛选出的 SARS-CoV-2 中和抗体与 ACE2-RBD 界面结合,并且对大多数已知的 RBD 突变具有耐受性。
Cell Rep. 2021 Jul 27;36(4):109433. doi: 10.1016/j.celrep.2021.109433. Epub 2021 Jul 7.
10
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.